CM Management’s Theravance Biopharma TBPH Stock Holding History

CM Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-120,000	Closed	-$1.15M	–	75
2022 Q1	$1.15M	Buy	120,000 +70,000	+140%	+$686K	0.96%	33
2021 Q4	$553K	Sell	50,000 -50,000	-50%	-$436K	0.42%	68
2021 Q3	$740K	Buy	100,000 +50,000	+100%	+$559K	0.55%	60
2021 Q2	$726K	Hold	50,000	–	–	0.52%	65
2021 Q1	$1.02M	Buy	+50,000	New	+$950K	0.76%	56

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CM Management's TBPH Position: Q2 2022 in Review

CM Management sold out of Theravance Biopharma (TBPH) in Q2 2022, closing a stake of 120,000 shares — an estimated $1.15M sold.

CM Management first reported a position in TBPH in Q1 2021 and held it in 5 quarters. The position peaked at $1.15M in Q1 2022. 113 funds tracked by Wall St. Rank hold TBPH as of Q2 2022.

CM Management reported no remaining Theravance Biopharma position as of Q2 2022 after selling out during the quarter.
CM Management sold 120,000 Theravance Biopharma shares in Q2 2022, an estimated $1.15M.
CM Management first reported a position in Theravance Biopharma in Q1 2021 and held it in 5 quarters.
CM Management's Theravance Biopharma position peaked at $1.15M in Q1 2022.
113 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2022.

Based on CM Management's 13F filing for Q2 2022, filed 8 Aug 2022.